Aggressive tPA stroke treatment promises lower long-term costs
The FDA approved use of tissue plasminogen activator (tPA) for stroke in 1996, but it took another 10 years for the Centers for Medicare and Medicaid Services to offer reimbursement. The agency's decision is part of a larger trend that recognizes the value of preventive care and treatment compared with the cost of longer hospital stays.
The FDA approved use of tissue plasminogen activator (tPA) for stroke in 1996, but it took another 10 years for the Centers for Medicare and Medicaid Services to offer reimbursement. The agency's decision is part of a larger trend that recognizes the value of preventive care and treatment compared with the cost of longer hospital stays.
"The idea of spending a lot of resources up front on stroke patients is gaining momentum. The fact that CMS recently raised the payment amount for acute stroke is recognition from the government that the acute care setting is a small fraction of the true costs of stroke management.
"If you spend more money on stroke patients in the first two days in the hospital, you can save money in the long run because the patients get better. Studies have shown that inpatient costs are about 3% of the overall costs of a stroke. If you double that amount and if you also reduce bad outcomes by 5%, you've more than paid for yourself, not to mention you have 5% more people with better outcomes."
-Dr. A. Greg Sorensen, a staff neuroradiologist at Massachusetts General Hospital and director of its Center for Biomarkers in Imaging.
Where Things Stand with the Radiologist Shortage
June 18th 2025A new report conveys the cumulative impact of ongoing challenges with radiologist residency positions, reimbursement, post-COVID-19 attrition rates and the aging of the population upon the persistent shortage of radiologists in the United States.
How to Successfully Launch a CCTA Program at Your Hospital or Practice
June 11th 2025Emphasizing increasing recognition of the capability of coronary computed tomography angiography (CCTA) for the evaluation of acute and stable chest pain, this author defuses common misperceptions and reviews key considerations for implementation of a CCTA program.
The Reading Room: Artificial Intelligence: What RSNA 2020 Offered, and What 2021 Could Bring
December 5th 2020Nina Kottler, M.D., chief medical officer of AI at Radiology Partners, discusses, during RSNA 2020, what new developments the annual meeting provided about these technologies, sessions to access, and what to expect in the coming year.
Mammography AI Platform for Five-Year Breast Cancer Risk Prediction Gets FDA De Novo Authorization
June 2nd 2025Through AI recognition of subtle patterns in breast tissue on screening mammograms, the Clairity Breast software reportedly provides validated risk scoring for predicting one’s five-year risk of breast cancer.
